People · Operator
Named in public records as an officer, director or promoter · active 2020–2020 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Interius BioTherapeutics, Inc. | — | Biotechnology | Series C | $118.1M | $478.9M | 2020 |
Saar Gill at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Saar Gill on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Leon O. Moulder, Jr. | 1 | 6 |
| Bruce Peacock | 1 | 5 |
| Leon O. Moulder | 1 | 2 |
| Philip R. Johnson, M.D. | 1 | 2 |
| Benjamin R. Lund | 1 | 2 |
| Philip R. Johnson | 1 | 2 |
| Lori R. Forrest | 1 | 1 |
| Tomas R. Kiselak | 1 | 1 |
| Bihua O. Chen | 1 | 1 |
| Leon R. Moulder, Jr. | 1 | 1 |
| Dora R. Mitchell | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.